FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200360020> ?p ?o ?g. }

• W4200360020 abstract "The emerging data supports rhythm control to prevent major adverse cardiac events (MACE) in high-risk patients with atrial fibrillation (AF). Limited data demonstrated rivaroxaban 10 mg combining dronedarone seemed feasible. This study aimed at investigating clinical events in a dronedarone-treated cohort. This exploratory, retrospective chart review was conducted in nonpermanent AF patients receiving dronedarone for ≥ 3 months between 2009/1 and 2016/2. In Taiwan, dronedarone's labeled indication was strict to age ≥ 70 or 65 to 70 years with either hypertension, diabetes, prior stroke, or left atrium >50 mm. We divided all into 4 groups using antithrombotic strategies to evaluate the safety, effectiveness, and MACE endpoints. A total of 689 patients (mean CHA2DS2-VASc score 3.8 ± 1.4) were analyzed: rivaroxaban 10 mg (n = 93, 13.5%), warfarin (n = 89, 12.9%), antiplatelet (n = 331, 48.0%), and none (n = 176, 25.5%). During the follow-up period (mean 946 ± 493.8 days), the rivaroxaban group did not report any stroke or thromboembolism (ishcmeic stroke rate: antiplatelet [0.6%], none [1.1%]; hemorrahgic stroke rate: warfarin [2.2%]; thromboembolism rate: warfarin [2.2%]). There was no significant difference in safety, effectiveness, and MACE endpoints between groups. Also, >104 weeks of dronedarone use was the independent predictor for MACE after adjusting the strategy and other covariates (hazard ratio 0.14 [95% confidence interval 0.04-0.44], P = .001). Our findings warrant concomitant rivaroxaban 10 mg and dronedarone for further investigation. Regardless of antithrombotic strategies, a more extended persistence of dronedarone was associated with fewer MACE." @default.
• W4200360020 created "2021-12-31" @default.
• W4200360020 creator A5006665553 @default.
• W4200360020 creator A5011305487 @default.
• W4200360020 creator A5015130639 @default.
• W4200360020 creator A5023632351 @default.
• W4200360020 creator A5028571272 @default.
• W4200360020 creator A5033900908 @default.
• W4200360020 creator A5042149613 @default.
• W4200360020 creator A5050070379 @default.
• W4200360020 creator A5052575073 @default.
• W4200360020 creator A5066234713 @default.
• W4200360020 creator A5079274453 @default.
• W4200360020 creator A5088229076 @default.
• W4200360020 creator A5090363899 @default.
• W4200360020 date "2021-01-01" @default.
• W4200360020 modified "2023-10-18" @default.
• W4200360020 title "Exploratory Evaluation of Rhythm Control by Dronedarone in Combination With Low-Dose Rivaroxaban, Warfarin, Antiplatelet, or None of the Antithrombotic Therapy in High-Risk Patients With Non-Permanent Atrial Fibrillation: A Retrospective Cohort Study" @default.
• W4200360020 cites W1985993462 @default.
• W4200360020 cites W1986637035 @default.
• W4200360020 cites W2012838115 @default.
• W4200360020 cites W2020866745 @default.
• W4200360020 cites W2025908365 @default.
• W4200360020 cites W2082047949 @default.
• W4200360020 cites W2107482271 @default.
• W4200360020 cites W2110253 @default.
• W4200360020 cites W2121703474 @default.
• W4200360020 cites W2155732986 @default.
• W4200360020 cites W2157409700 @default.
• W4200360020 cites W2161696103 @default.
• W4200360020 cites W2164861810 @default.
• W4200360020 cites W2509795914 @default.
• W4200360020 cites W2553397353 @default.
• W4200360020 cites W2794260680 @default.
• W4200360020 cites W2811091687 @default.
• W4200360020 cites W2906131233 @default.
• W4200360020 cites W3082188176 @default.
• W4200360020 cites W3082794714 @default.
• W4200360020 cites W3116672078 @default.
• W4200360020 cites W4233664165 @default.
• W4200360020 cites W4292280632 @default.
• W4200360020 doi "https://doi.org/10.1177/10760296211052968" @default.
• W4200360020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34894780" @default.
• W4200360020 hasPublicationYear "2021" @default.
• W4200360020 type Work @default.
• W4200360020 citedByCount "0" @default.
• W4200360020 crossrefType "journal-article" @default.
• W4200360020 hasAuthorship W4200360020A5006665553 @default.
• W4200360020 hasAuthorship W4200360020A5011305487 @default.
• W4200360020 hasAuthorship W4200360020A5015130639 @default.
• W4200360020 hasAuthorship W4200360020A5023632351 @default.
• W4200360020 hasAuthorship W4200360020A5028571272 @default.
• W4200360020 hasAuthorship W4200360020A5033900908 @default.
• W4200360020 hasAuthorship W4200360020A5042149613 @default.
• W4200360020 hasAuthorship W4200360020A5050070379 @default.
• W4200360020 hasAuthorship W4200360020A5052575073 @default.
• W4200360020 hasAuthorship W4200360020A5066234713 @default.
• W4200360020 hasAuthorship W4200360020A5079274453 @default.
• W4200360020 hasAuthorship W4200360020A5088229076 @default.
• W4200360020 hasAuthorship W4200360020A5090363899 @default.
• W4200360020 hasBestOaLocation W42003600201 @default.
• W4200360020 hasConcept C126322002 @default.
• W4200360020 hasConcept C127413603 @default.
• W4200360020 hasConcept C164705383 @default.
• W4200360020 hasConcept C207103383 @default.
• W4200360020 hasConcept C2776301958 @default.
• W4200360020 hasConcept C2777015399 @default.
• W4200360020 hasConcept C2778094803 @default.
• W4200360020 hasConcept C2778661090 @default.
• W4200360020 hasConcept C2779161974 @default.
• W4200360020 hasConcept C2779518148 @default.
• W4200360020 hasConcept C2780400711 @default.
• W4200360020 hasConcept C2780645631 @default.
• W4200360020 hasConcept C2780739214 @default.
• W4200360020 hasConcept C42219234 @default.
• W4200360020 hasConcept C44249647 @default.
• W4200360020 hasConcept C500558357 @default.
• W4200360020 hasConcept C71924100 @default.
• W4200360020 hasConcept C78519656 @default.
• W4200360020 hasConceptScore W4200360020C126322002 @default.
• W4200360020 hasConceptScore W4200360020C127413603 @default.
• W4200360020 hasConceptScore W4200360020C164705383 @default.
• W4200360020 hasConceptScore W4200360020C207103383 @default.
• W4200360020 hasConceptScore W4200360020C2776301958 @default.
• W4200360020 hasConceptScore W4200360020C2777015399 @default.
• W4200360020 hasConceptScore W4200360020C2778094803 @default.
• W4200360020 hasConceptScore W4200360020C2778661090 @default.
• W4200360020 hasConceptScore W4200360020C2779161974 @default.
• W4200360020 hasConceptScore W4200360020C2779518148 @default.
• W4200360020 hasConceptScore W4200360020C2780400711 @default.
• W4200360020 hasConceptScore W4200360020C2780645631 @default.
• W4200360020 hasConceptScore W4200360020C2780739214 @default.
• W4200360020 hasConceptScore W4200360020C42219234 @default.
• W4200360020 hasConceptScore W4200360020C44249647 @default.
• W4200360020 hasConceptScore W4200360020C500558357 @default.
• W4200360020 hasConceptScore W4200360020C71924100 @default.
• W4200360020 hasConceptScore W4200360020C78519656 @default.
• W4200360020 hasLocation W42003600201 @default.
• W4200360020 hasLocation W42003600202 @default.
• W4200360020 hasLocation W42003600203 @default.

• next